[Desk's View] Requirements for Priority Marketing Authorization system entry

It has been a decade since the introduction of the Priority Marketing Authorization system. Launched in March 2015 alongside the implementation of the Approval-Patent Linkage System under the South Korea-US FTA negotiations, the Priority Marketing Authorization has become a core system of generic marketing authorization.

The system's foundational framework has remained unchanged for the past 10 years. Securing three specific requirements grants a 9-month window of market exclusivity. To obtain first generic exclusivity, a developer must satisfy three criteria. First, filing the initial patent challenge against the original patent; second, receiving a favorable trial decision upholding the challenge; and third, submitting the earliest application for marketing authorization.  

Over the past decade, the generic regulatory system has undergone notable changes, including the implementation of the "1+3 limit" on shared and sub-consigned bioequivalence (BE) studies, alongside drug pricing adjustments that preserve higher price tiers only for generics backed by independently conducted BE trials. These institutional shifts are driving a structural rationalization within the generic drug sector.  

However, critics point out that the requirements for Priority Marketing Authorization do not align with shifting market realities. In particular, the provision governing the initial patent challenge is cited as a major factor eroding the practical value of generic market exclusivity. This is because the qualification is not limited to the first company to file a patent challenge, but extends to any competitor that files its own challenge within 14 days of that initial filing date.  

Drop-in filings often occur after an initial patent challenge is logged, as generic developers rush to secure co-exclusivity rights within the 14-day window to avoid falling behind on commercial launch timelines.  

While challengers must still secure a favorable trial decision and meet the earliest marketing authorization application requirement, it has become commonplace for firms to rush to satisfy the initial filing condition before mapping out an actual downstream strategy. These patent challenges place an immense administrative strain on the Intellectual Property Trial and Appeal Board (IPTAB) and resulting in a substantial waste of public and corporate resources due to ballooning litigation costs.

Ultimately, the broad granting of exclusivity status to a large pack of concurrent applicants dilutes the commercial value of market exclusivity, undermining the core regulatory intent and utility of the system.

As a result, voices within the sector are calling for the outright elimination of the 14-day grace period clause from the initial patent challenge requirement.

Restricting eligibility for exclusivity to the single firm that executes the initial patent challenge would discourage the influx of indiscriminate generic filings and significantly strengthen the commercial value of generic exclusivity.

Yet, given the unique dynamics of the South Korean pharmaceutical landscape, where more than 100 drugmakers compete in the generic space, abolishing the 14-day rule could be perceived by some as granting an unfair advantage to a single company or as systematically depriving competitors of market opportunities.  

Furthermore, since identical generics can enter the market immediately after the exclusivity window closes, and non-identical alternatives, such as salt variations, can bypass the marketing exclusivity altogether, limiting these exclusivity rights to a single developer dose not eliminate competitive dynamics from the marketplace.

Granting a market-exclusivity window to a single firm would amplify the practical impact of the system and prevent competition driven by a surplus of identical products. Furthermore, this mechanism could act as a catalyst for structural rationalization, encouraging high-value pipeline over speculative generic development.

Changes across foundational marketing authorization and drug pricing frameworks are evident. It is now the time to recalibrate policies governing patent challenges, which represent the true starting point of generic development. The Ministry of Food and Drug Safety (MFDS) must not dismiss the recommendations from the Approval-Patent Linkage System impact assessment report published late last year, which strongly emphasized the urgent need to elevate the practical effectiveness of the Priority Marketing Authorization.